34
Participants
Start Date
March 21, 2017
Primary Completion Date
December 6, 2017
Study Completion Date
December 6, 2017
Mepolizumab 100 mg
Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
Placebo matching mepolizumab
Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Norfolk
GSK Investigational Site, Sandy Springs
GSK Investigational Site, Louisville
GSK Investigational Site, Indianapolis
GSK Investigational Site, New Albany
GSK Investigational Site, Chicago
GSK Investigational Site, Fort Smith
GSK Investigational Site, San Antonio
GSK Investigational Site, Santa Ana
GSK Investigational Site, Fremont
GSK Investigational Site, Surrey
GSK Investigational Site, Vancouver
GSK Investigational Site, Barrie
GSK Investigational Site, Markham
GSK Investigational Site, Oakville
GSK Investigational Site, Ottawa
GSK Investigational Site, Peterborough
GSK Investigational Site, Richmond Hill
GSK Investigational Site, Québec
Lead Sponsor
GlaxoSmithKline
INDUSTRY